Company / EPS (Diluted)
Oric Pharmaceuticals, Inc. EPS (Diluted) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.47
FY2025
5-year range
-$2.25 / -$1.47
FY2021-FY2025
Trend
+19.7%
vs FY2024
Sector context
#106 of 204
Health Care
What the data says
At $-1.47, Oric Pharmaceuticals, Inc.'s eps (diluted) ranks #106 of 204 in the Health Care sector. EPS (Diluted) has increased for 3 consecutive years, from $-2.25 in FY2022 to $-1.47 in FY2025.
Based on SEC 10-K filings.
-1.47 in FY2025.
Improved from $-1.96 to $-1.47 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#106 of 204 in Health CareTop 52% of 204This company -$1.47 Sector average -$0.89
▼
-65.9% below sector average
Key checks
Key Insights
- Oric Pharmaceuticals, Inc.'s eps (diluted) has grown for 3 consecutive years.
- In FY2025, eps (diluted) increased 19.7% year-over-year.
- Ranks #106 out of 204 companies in the Health Care sector.
- Lowest eps (diluted) in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 5.96 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.47 | +19.7% |
| FY2024 | -$1.83 | +6.6% |
| FY2023 | -$1.96 | +12.9% |
| FY2022 | -$2.25 | -8.7% |
| FY2021 | -$2.07 | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026